These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 6093527)

  • 21. Outpatient use of ceftriaxone: a cost-benefit analysis.
    Poretz DM; Woolard D; Eron LJ; Goldenberg RI; Rising J; Sparks S
    Am J Med; 1984 Oct; 77(4C):77-83. PubMed ID: 6093525
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Cost-effectiveness comparative study of ceftriaxone verus cefotaxime in the treatment of complicated urinary infections].
    Martínez Jabaloyas JM; Sanz Chinesta S; Jiménez Cruz JF; Flores Corral N; Unda Urzaiz M; Leiva Galvis O; González Romojaro V; Hernández Fernández C; Lledó García E; Rioja Sanz LA; Gonzalvo Ibarra A; Camacho González JE; Ruíz Alvárez-Cienfuegos F; Resel Estévez L; Corral Saleta J; Burgos Rodríguez R; Del Rosal Samaniego JM
    Actas Urol Esp; 1997; 21(7):668-74. PubMed ID: 9412209
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Ceftriaxone (Rocéphine) in major African infectious pathology. Results at the Niamey Hospital (Niger) ].
    Rey JL; Konarjevski R; Madras R; Ousseini A; Félix H
    Pathol Biol (Paris); 1982 Jun; 30(6 Pt 2):513-6. PubMed ID: 6289228
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative experimental antibacterial activity of ceftriaxone (Ro 13-9904).
    Böhni E
    Chemioterapia; 1984 Feb; 3(1):25-32. PubMed ID: 6100173
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ceftriaxone administered once or twice a day for treatment of bacterial infections of childhood.
    Higham M; Cunningham FM; Teele DW
    Pediatr Infect Dis; 1985; 4(1):22-6. PubMed ID: 3969362
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Normal values for GOT and GPT with new optimized methods (author's transl)].
    Sitzmann FC; Löw C; Kaloud H; Prestele H
    Klin Padiatr; 1974 Jul; 186(4):346-52. PubMed ID: 4472915
    [No Abstract]   [Full Text] [Related]  

  • 27. Once-daily ceftriaxone therapy for serious bacterial infections in children.
    Congeni BL; Chonmaitree T; Rakusan TA; Box QT
    Antimicrob Agents Chemother; 1985 Feb; 27(2):181-3. PubMed ID: 3985602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of lower respiratory tract infections with ceftriaxone and cefotaxime. A comparative study.
    Abbate GF; Alagia I; Giaquinto E; Leonessa V; Savioli L; Altucci P; Caputi M; Guarino C; Micillo E; Catena E
    Respiration; 1986; 49(3):222-30. PubMed ID: 3515468
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ceftriaxone therapy in pediatric patients.
    Harrison CJ; Welch D; Marks MI
    Am J Dis Child; 1983 Nov; 137(11):1048-51. PubMed ID: 6314806
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ceftriaxone once daily compared with four daily doses of cefotaxime in the treatment of severe gram-negative septicemia or pyemia: a randomized study.
    Leu HS; Lasserre R
    Changgeng Yi Xue Za Zhi; 1995 Mar; 18(1):36-42. PubMed ID: 7767852
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The safety profile of ofloxacin.
    Tack KJ; Smith JA
    Am J Med; 1989 Dec; 87(6C):78S-81S. PubMed ID: 2690623
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of ceftriaxone in serious pediatric infections.
    Aronoff SC; Murdell D; O'Brien CA; Klinger JD; Reed MD; Blumer JL
    Antimicrob Agents Chemother; 1983 Nov; 24(5):663-6. PubMed ID: 6318653
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of ceftriaxone in treatment of serious childhood infections.
    Chadwick EG; Connor EM; Shulman ST; Yogev R
    J Pediatr; 1983 Jul; 103(1):141-5. PubMed ID: 6306193
    [No Abstract]   [Full Text] [Related]  

  • 34. Ceftriaxone therapy of bone and soft tissue infections in hospital and outpatient settings.
    Eron LJ; Park CH; Hixon DL; Goldenberg RI; Poretz DM
    Antimicrob Agents Chemother; 1983 May; 23(5):731-7. PubMed ID: 6307135
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nephrolithiasis associated with ceftriaxone therapy: a prospective study in 51 children.
    Avci Z; Koktener A; Uras N; Catal F; Karadag A; Tekin O; Degirmencioglu H; Baskin E
    Arch Dis Child; 2004 Nov; 89(11):1069-72. PubMed ID: 15499067
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Once-daily ceftriaxone for skin and soft tissue infections.
    Gordin FM; Wofsy CB; Mills J
    Antimicrob Agents Chemother; 1985 Apr; 27(4):648-9. PubMed ID: 4004197
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neutropenia during therapy with ceftriaxone.
    Thomas MG; Peat B; Lang SD
    N Z Med J; 1985 Jan; 98(771):23-4. PubMed ID: 3855513
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparative toxicities of third-generation cephalosporins.
    Meyers BR
    Am J Med; 1985 Aug; 79(2A):96-103. PubMed ID: 4025384
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nonchemotherapy drug-induced agranulocytosis in children detected by a prospective pharmacovigilance program.
    Medrano-Casique N; Tong HY; Borobia AM; Carcas AJ; Frías J; Ramírez E
    Pediatr Hematol Oncol; 2016; 33(7-8):441-456. PubMed ID: 27922762
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Age-associated changes in ceftriaxone pharmacokinetics.
    Hayton WL; Stoeckel K
    Clin Pharmacokinet; 1986; 11(1):76-86. PubMed ID: 3948454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.